A Study of U3-1402 in Subjects With Metastatic Breast Cancer
Status:
Recruiting
Trial end date:
2023-11-30
Target enrollment:
Participant gender:
Summary
This study is to evaluate safety and efficacy of an antibody drug conjugate U3-1402 in
patients with metastatic breast cancer (MBC) who have received no prior anti-HER2 therapy.